Orexo announces positive Phase III results for KW-2246 in Japan

27-Jul-2009 - Orexo’s partner in Japan, Kyowa Hakko Kirin, has obtained positive phase III results in Japan for KW-2246, which is approved for the treatment of breakthrough pain in cancer patients and marketed under the brand AbstralTM in Europe. Kyowa Hakko Kirin will now proceed with preparations for a ...

Orexo and Boehringer Ingelheim Extend Their Research Collaboration

10-Sep-2008 - Orexo AB and Boehringer Ingelheim have extended their existing three year research collaboration for a further 12 months from November 2008. The research collaboration is a part of an exclusive world-wide license to develop and market a new class of drugs with a novel mechanism of action for the ...

Orexo receives 2 million EURO in milestone payment for approval of the pain product Rapinyl

06-Sep-2006 - Orexo´s European licensing partner ProStrakan Group plc. has announced submission of a New Drug Application for approval of the pain product Rapinyl in Europe. Orexo receives a milestone payment of 2 million EURO in connection with this announcement. The license agreement with ProStrakan Group ...

Orexo acquires Noster System to strengthen its position in stomach-ulcer diagnostics

02-May-2006 - Orexo´s subsidiary Kibion AB has acquired the majority of the shares in Noster System AB. Kibion AB has also offered to purchase the remaining shares in Noster System. The acquisition is conditional upon Kibion AB acquiring more than 90 percent of all shares in Noster System. Noster System, with ...

Orexo's stock market move sends positive signal for biotech industry

15-Nov-2005 - After a couple of rough years in the biotechnology sector, things are finally looking up again. The news that Uppsala-based Orexo is to list on the stock market -making it one of the few listed Swedish biotech companies - sends a positive signal for the future. Orexo can look back on ten ...

Orexo sells its peptide technology

20-Jun-2005 - Orexo AB has sold the rights for its cell-penetrating peptide technology, CPP. "Orexo's strategy is to regularly evaluate and analyze both its products and technologies," says Zsolt Lavotha, President and CEO of Orexo AB. "Today, we have a portfolio of several product candidates at different ...

Orexo expands further - broadens operations and recruits new employees

02-Feb-2005 - Orexo continues to expand. During the first half of 2005, a new, directly owned analytical laboratory will become operational, strengthening the company's ability to accelerate the development of its´ product portfolio. Furthermore, additional expertise has been recruited to facilitate this ...

Orexo accelerates its portfolio development

Dr. Nils-Otto Ahnfelt assumes position as Project Director

01-Feb-2005 - Orexo is further strengthening its organization through the recruitment of Dr. Nils-Otto Ahnfelt as Project Director, with the task of driving development of the company's product portfolio on a project basis. Dr. Ahnfelt will also be a member of Orexo's executive management team. Nils-Otto ...